

AGENDA EORTC Gynecological Cancer Group Fall Meeting 2015

09 – 10 October 2015

*EramusMC, Gk building
Rotterdam, The Netherlands*

Friday 09 October 2015		
Time slot	Topic / Title of presentation	Moderator
10.00 – 12.00	Young Investigator Meeting	N. Ottevanger/A. Casado
<i>12.00 – 13.00</i>	<i>Lunch</i>	
13.00 – 15.30	<p>Ovarian Tumour Site Committee (N. Ottevanger)</p> <ul style="list-style-type: none"> ▪ EORTC 1508: A phase II study of antiPDL-1 antibody atezolizumab, bevacizumab and aspirin to investigate safety, biological activity and immunological mechanisms of this combination in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma (<i>EORTC GCG PI: A. Wolfer</i>) ▪ EORTC 55092: Phase Ib/II of pazopanib and weekly paclitaxel / carboplatin in recurrent platin resistant ovarian carcinoma (<i>EORTC GCG PI: I. Vergote</i>). ▪ New proposals <p>Endometrial Tumour Site Committee (F. Amant)</p> <ul style="list-style-type: none"> ▪ EORTC 1528: A randomized phase II study of lenvatinib versus doxorubicine in second line advanced or recurrent endometrial cancer. (<i>EORTC GCG PI: A. Casado</i>) ▪ EORTC 1212. DGCG/NCRI (GCIG/ENGOT proposal). Vargatef in recurrent clear cell ovarian and endometrial cancer (<i>EORTC GCG PI: A. Westermann</i>). • EORTC 55116-62114. (EORTC/CRUK/NCI) A phase III trial of gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited high grade uterine leiomyosarcoma (<i>GOG PI: Martee Hensley, EORTC GCG PI: N. Ottevanger</i>). • EORTC 62113-55115. (EORTC/CRUK/NCI) A randomized phase II study of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma. (<i>EORTC STBSG PI: I. Ray Coquard. EORTC GCG PI: N. Reed.</i>) • ENGOT-EN2-DGCG / EORTC 55102: A phase III trial of chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer. (<i>DGCG PI: M. Raza Mirza; EORTC PI: F. Amant</i>). • New proposals 	N. Ottevanger

AGENDA EORTC Gynecological Cancer Group Fall Meeting 2015

09 – 10 October 2015

*EramusMC, Gk building
Rotterdam, The Netherlands*

<i>15.30 - 16.00</i>	<i>Coffee break</i>	
16.00 – 17.00	Cervix Tumor Site Committee. (G. Kenter) <ul style="list-style-type: none"> • EORTC 55994: Phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer (EORTC GCG PI: G. Kenter). • New proposals 	N. Ottevanger
17.00 – 18.00	Quality Assurance Subcommittee	N. Ottevanger
<i>19.00 -</i>	<i>Dinner</i>	

AGENDA EORTC Gynecological Cancer Group Fall Meeting 2015

09 – 10 October 2015

*EramusMC, Entrance B
Rotterdam, The Netherlands*

Saturday 10 October 2015		
Time slot	Topic / Title of presentation	Moderator
09.00 – 10.00	General Assembly and Business meeting <ul style="list-style-type: none"> • EORTC HQ report (<i>N. Ottevanger,, A. Atasoy</i>) • EORTC GCG future meetings <ul style="list-style-type: none"> ◦ EORTC GCG spring meeting, Madrid 8-9 April 2016 (local organizer A. Casado) ◦ EORTC GCG fall meeting, Lausanne 11-12 November 2016 (local organizer F. Herrera, A. Wolfer) • New applications and reapplications in members (<i>F. Herrera/N. Ottevanger</i>) • Financial report (<i>A. Casado</i>) 	N. Ottevanger
10.00 – 11.00	Report on past meetings and activities <ul style="list-style-type: none"> • Report from GCIG meetings • Report from ENGOT meetings • Bibliography update: Pending publications 	N. Ottevanger
<i>11.00 – 11.30</i>	<i>Coffee break</i>	
11.30 – 12.30	Translational Research Committee <ul style="list-style-type: none"> • Presentation by dr. Maurizio D'Incalci (Mario Negri Institute Milano): <i>"Unique mechanism of action of Trabectedin on cancer cells and tumor microenvironment: Clinical applications"</i> 	P. Berns
12.30 – 13.00	Survivorship program and new projects <ul style="list-style-type: none"> • Follow-up in Gynecological Cancer Survivors: An EORTC QLQ-GCG Survivorship Protocol 	E. Van Dorst/E. Greimel
<i>13.00 – 14.00</i>	<i>Lunch</i>	
14.00 – 16.00	Report from the ROG-GCG WORKING PARTY (F Herrera) <ul style="list-style-type: none"> • EORTC 1411: A Phase II trial of chemoradiotherapy in combination with VGX-3100 and INO-9012 in Locally Advanced Cervical Cancer (<i>EORTC GCG PI: F. Herrera</i>) • New proposals Radiotherapy subcommittee (F. Herrera, E. van der Steen)	N. Ottevanger

AGENDA EORTC Gynecological Cancer Group Fall Meeting 2015

09 – 10 October 2015

*EramusMC, Entrance B
Rotterdam, The Netherlands*

	Surgery subcommittee (E. Van Dorst) Chemotherapy subcommittee (A. Casado)	
16.00 – 16.30	Protocol Committee	N. Ottevanger/A. Casado